Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 14, 2022 07:30 ET | Source: Reunion Neuroscience Inc.

Reunion Neuroscience Inc. Provides Business Update and Reports Fiscal Second Quarter 2023 Financial Results

Completed RE104 Phase 1 prespecified dose cohorts and on track to deliver interim Phase 1 analysis in the first calendar quarter of 2023.Appointed Greg Mayes as President and Chief Executive Officer,...
November 07, 2022 07:30 ET | Source: Reunion Neuroscience Inc.

Reunion Neuroscience Schedules Fiscal Second Quarter 2023 Conference Call for Monday, November 14, 2022, at 8:30 A.M. ET

TORONTO, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) ("Reunion" or the “Company”), a biopharmaceutical company committed to developing innovative...
October 31, 2022 07:30 ET | Source: Reunion Neuroscience Inc.

Reunion Neuroscience to Present at Upcoming November Conferences

TORONTO, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) ("Reunion" or the “Company”), a biopharmaceutical company committed to developing innovative...
October 24, 2022 07:30 ET | Source: Reunion Neuroscience Inc.

Reunion Neuroscience Appoints Chief Financial Officer and Vice President, Medical Affairs

TORONTO, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) ("Reunion" or the “Company”), a biopharmaceutical company committed to developing innovative...
October 12, 2022 07:30 ET | Source: Reunion Neuroscience Inc.

Reunion Neuroscience CEO to Participate on Panel at 2022 Horizons Perspectives on Psychedelics Conference

TORONTO, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) ("Reunion" or the “Company”), a leader in novel serotonergic psychedelic drug development committed to...
October 07, 2022 17:30 ET | Source: Reunion Neuroscience Inc.

Reunion Neuroscience Inc. Announces Executive Changes

TORONTO, Oct. 07, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) ("Reunion" or the “Company”), a leader in novel psychedelic drug development committed to innovating...
October 03, 2022 07:30 ET | Source: Reunion Neuroscience Inc.

Reunion Neuroscience to Participate in the Cantor Neurology & Psychiatry Conference

TORONTO, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX: REUN, Nasdaq: REUN) ("Reunion"), or (“the Company”), a global leader in the discovery and development of innovative...
September 29, 2022 17:20 ET | Source: Reunion Neuroscience Inc.

Reunion Neuroscience Inc. Announces Results of Annual General and Special Shareholder Meeting

TORONTO, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) ("Reunion" or the “Company”) today announced the results of the votes held at its September 29, 2022...
September 28, 2022 07:30 ET | Source: Reunion Neuroscience Inc.

Reunion Neuroscience Inc. Appoints Greg Mayes as President and Chief Executive Officer

TORONTO, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) ("Reunion" or the “Company”), a leader in novel psychedelic drug development committed to innovating...
September 08, 2022 08:00 ET | Source: Reunion Neuroscience Inc.

Reunion Neuroscience Inc. to Participate in Upcoming Investor Conferences

TORONTO, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX: REUN, Nasdaq: REUN) ("Reunion"), or (“the Company”), a global leader in the discovery and development of innovative...